ATLANTA--(BUSINESS WIRE)--Cotiviti Holdings Inc. (NYSE:COTV) (“Cotiviti”), a leading provider of analytics-driven payment accuracy solutions primarily focused on the healthcare industry, today announced financial results for the three months ended March 31, 2017. Cotiviti will host a conference call on May 3, 2017 at 8:30 a.m. Eastern Time to discuss its results.
“Our team’s continued focus on delivering value to our clients translated into solid 2017 first quarter results for Cotiviti,” said Doug Williams, Chief Executive Officer. “Our financial model is tightly aligned with client value creation, resulting in first quarter overall revenue growth of 12% from the prior year to $160.1 million and adjusted EBITDA growth of 14% to $57.7 million.”
“Cotiviti’s leadership position in both healthcare and retail payment accuracy provides meaningful ongoing growth opportunities as we expand relationships with existing clients through the adoption of new solutions and cross-selling, and add new clients to our roster,” continued Williams. “Over the past year, 95% of our healthcare revenue growth was from existing clients and we added three new healthcare clients in the first quarter.”
“Cotiviti is well positioned to support our clients as they work to enhance their payment accuracy with their providers. With our unique analytics-driven solutions, proprietary technology platform and the expertise of our talented team, we remain focused on providing valuable solutions that effectively address the payment accuracy portion of the nearly $1 trillion of annual healthcare industry waste,” Williams concluded.
“As a result of the strength of our business model and adjusted EBITDA margin expansion, we reduced our net leverage ratio to 2.7 times at March 31, 2017 from 2.9 times at year-end 2016,” said Steve Senneff, Chief Financial Officer. “Using our strong cash flow, we will continue to make strategic investments in technology and analytics to evolve our payment accuracy solutions benefiting our clients and the broader healthcare industry cost containment efforts.”
First Quarter 2017 Financial Results
- Total revenue for the quarter increased 12% to $160.1 million, compared to $142.7 million in the first quarter a year ago. Revenue growth was driven by a 13% increase in the Healthcare segment to $139.8 million, with the Global Retail and Other segment contributing $20.3 million, up 9% compared to the same period a year ago. Healthcare revenue was favorably impacted in the quarter by an increase in volume and expanded adoption of solutions within Cotiviti’s existing healthcare clients. Retail revenue increased primarily due to the accelerated timing of certain large payment settlements which increased revenue approximately $2 million in the first quarter 2017.
- Net income increased 234% to $27.0 million, or $0.28 per diluted share for the first quarter, compared to $8.1 million in the prior year quarter, or $0.10 per diluted share. First quarter 2017 net income was favorably impacted by a lower effective tax rate from a $10.4 million tax benefit from stock option exercises recognized during the quarter, a 48% decline in interest expense from a year ago, and year-over-year revenue growth.
- Non-GAAP Adjusted EBITDA for the quarter was $57.7 million, a 14% increase compared to $50.6 million for the quarter a year ago.
- Non-GAAP Adjusted Net Income for the quarter was $32.0 million, or $0.34 per diluted share, compared to $22.3 million, or $0.29 per diluted share a year ago.
Cotiviti provides full year 2017 guidance as follows:
- Total revenue in a range of $688 million - $700 million;
- Adjusted EBITDA in a range of $266 million - $272 million; and
- Fully diluted weighted average shares of approximately 97 million.
Adjusted EBITDA, Adjusted Net Income, and Adjusted Net Income per Diluted Share are non-GAAP financial measures. For an explanation of these as measures of the Company’s operating performance, refer to the reconciliation in “Non-GAAP Financial Measures.”
Conference Call Information
To participate in the conference call on May 3rd, domestic callers can dial (877) 883-0383 and international callers can dial (412) 902-6506 and provide the following conference passcode: 2825348. A webcast of the call will be accessible on the Investor page of Cotiviti’s website at http://investors.cotiviti.com.
Supplemental Financial Information
Supplemental financial information that is not part of this press release is available on the Investor page of Cotiviti’s website at http://investors.cotiviti.com.
Cotiviti is a leading payment accuracy provider that helps healthcare payers and retailers achieve their business objectives by unlocking value from the incongruities the company discovers in the complex interactions customers have with stakeholders. Cotiviti helps clients capture over $3.7 billion annually through improved payment accuracy. Cotiviti provides services to over twenty of the top twenty-five U.S. healthcare payers and eight of the top ten U.S. retailers.
This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are subject to risks and uncertainties. All statements other than statements of historical fact or relating to present facts or current conditions included in this press release are forward-looking statements. Forward-looking statements give our current expectations and projections relating to our financial condition, results of operations, plans, objectives, future performance and business. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “anticipate,” “estimate,” “expect,” “project,” “seek,” “plan,” “intend,” “believe,” “will,” “may,” “could,” “continue,” “likely,” “should,” and other words.
The forward-looking statements contained in this press release are based on assumptions that we have made in light of our industry experience and our perceptions of historical trends, current conditions, expected future developments and other factors that we believe are appropriate under the circumstances. These statements are not guarantees of performance or results. These assumptions and our future performance or results involve risks and uncertainties (many of which are beyond our control). Important factors that could cause actual results to differ materially from those in the forward-looking statements include; regional, national or global political, economic, business, competitive, market and regulatory conditions and the following: our inability to successfully leverage our existing client base by expanding the volume of claims reviewed and cross-selling additional solutions; improvements to healthcare claims and retail billing processes reducing the demand for our solutions or rendering our solutions unnecessary; healthcare spending fluctuations; our clients declining to renew their agreements with us or renewing at lower performance fee levels; inability to develop new clients; delays in implementing our solutions; system interruptions or failures, including cyber-security breaches, identity theft or other disruptions that could compromise our information; our failure to innovate and develop new solutions for our clients; our failure to comply with applicable privacy, security and data laws, regulations and standards; changes in regulations governing healthcare administration and policies, including governmental restrictions on the outsourcing of functions such as those that we provide; loss of a large client; consolidation among healthcare payers or retailers; slow development of the healthcare payment accuracy market; negative publicity concerning the healthcare payment industry or patient confidentiality and privacy; significant competition for our solutions; our inability to protect our intellectual property rights, proprietary technology, information, processes and know-how; compliance with current and future regulatory requirements; declines in contracts awarded through competitive bidding or our inability to re-procure contracts through the competitive bidding process; our failure to accurately estimate the factors upon which we base our contract pricing; our inability to manage our growth; our inability to successfully integrate and realize synergies from any future acquisitions or strategic partnerships; our failure to maintain or upgrade our operational platforms; our failure to reprocure our Medicare Recovery Audit Contractor program contract; litigation, regulatory or dispute resolution proceedings, including claims or proceedings related to intellectual property infringements; our inability to expand our retail business; our inability to manage our relationships with information suppliers, software vendors or utility providers; fluctuation in our results of operations; changes in tax rules; risks associated with international operations; our inability to realize the book value of intangible assets; our success in attracting and retaining qualified employees and key personnel; and general economic, political and market forces and dislocations beyond our control; risks related to our substantial indebtedness and holding company structure; volatility in bank and capital markets; our status as a controlled company and as an emerging growth company; and provisions in our amended and restated certificate of incorporation. Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements.
Any forward-looking statement made by us in this press release speaks only as of the date on which it is made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Non-GAAP Financial Measures
The Company defines Adjusted EBITDA as net income before depreciation and amortization, interest expense, other non-operating (income) expense such as foreign currency translation, income tax (benefit) expense, transaction-related expenses and other and stock-based compensation. The Company defines Adjusted Net Income and Adjusted Net Income per Diluted Share as net income adjusted for non-cash and other non-recurring items.
Management believes Adjusted EBITDA is useful because it provides meaningful supplemental information about our operating performance and facilitates period-to-period comparisons without regard to our financing methods, capital structure or other items that we believe are not indicative of our ongoing operating performance. Management believes Adjusted Net Income is useful because it provides meaningful supplemental information about our operating performance and facilitates period-to-period comparisons without regard to non-cash expenses and other items that are one-time in nature. In order to assure that all investors have access to similar data the Company has determined that it is appropriate to provide these non-GAAP financial measures. Management believes we are enhancing investors’ understanding of our business and our results of operations, as well as assisting them in evaluating how well we are executing our strategic initiatives. Adjusted EBITDA and Adjusted Net Income are intended as supplemental measures of our performance that are not required by, or presented in accordance with U.S. generally accepted accounting principles, or GAAP. Adjusted EBITDA and Adjusted Net Income are not determined in accordance with GAAP, and should not be considered in isolation or as an alternative to net income, income from operations, net cash provided by operating, investing or financing activities or other financial statement data presented as indicators of financial performance or liquidity, each as presented in accordance with GAAP.
Cotiviti Holdings, Inc.
Consolidated Balance Sheets
|Cash and cash equivalents||$||128,458||$||110,635|
|Accounts receivable, net of allowance for doubtful accounts of $648 and $851 at March 31, 2017 and December 31, 2016, respectively; and net of estimated allowance for refunds and appeals of $35,518 and $41,020 at March 31, 2017 and December 31, 2016, respectively||62,072||67,735|
|Prepaid expenses and other current assets||17,847||14,957|
|Total current assets||215,609||202,430|
|Property and equipment, net||70,286||67,640|
|Intangible assets, net||518,131||533,305|
|Other long-term assets||2,746||2,864|
|LIABILITIES AND STOCKHOLDERS' EQUITY|
|Current maturities of long-term debt||$||18,000||$||18,000|
|Accounts payable and accrued other expenses||26,736||23,162|
|Accrued compensation costs||29,379||58,589|
|Estimated liability for refunds and appeals||61,766||62,539|
|Total current liabilities||143,113||171,393|
|Other long-term liabilities||5,765||8,799|
|Deferred tax liabilities||119,759||120,533|
|Total long-term liabilities||883,872||891,534|
|Commitments and contingencies (Note 6)|
|Common stock ($0.001 par value; 600,000,000 shares authorized, 91,845,947 and 90,748,740 issued, and 91,838,470 and 90,741,340 outstanding at March 31, 2017 and December 31, 2016, respectively)||92||91|
|Additional paid-in capital||921,186||911,582|
|Accumulated other comprehensive loss||(6,161||)||(6,156||)|
|Treasury stock, at cost (7,477 and 7,400 shares at March 31, 2017 and December 31, 2016, respectively)||(101||)||(98||)|
|Total stockholders' equity||975,908||939,336|
|TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY||$||2,002,893||$||2,002,263|
Cotiviti Holdings, Inc.
Consolidated Statements of Comprehensive Income
(Unaudited, in thousands except per share data)
|Three Months Ended|
|Cost of revenue (exclusive of depreciation and amortization, stated separately below):|
|Other costs of revenue||6,686||5,398|
|Total cost of revenue||62,974||58,859|
|Selling, general and administrative expenses (exclusive of depreciation and amortization, stated separately below):|
|Other selling, general and administrative expenses||16,879||15,229|
|Total selling, general and administrative expenses||41,572||34,339|
|Depreciation and amortization of property and equipment||5,575||4,835|
|Amortization of intangible assets||15,199||15,207|
|Total operating expenses||126,051||113,480|
|Other expense (income):|
|Other non-operating (income) expense||(453||)||(299||)|
|Total other expense (income)||7,968||15,761|
|Income before income taxes||26,114||13,477|
|Income tax (benefit) expense||(861||)||5,393|
|Other comprehensive (loss) income, net of tax:|
|Foreign currency translation adjustments||57||(26||)|
|Change in fair value of derivative instruments||(62||)||(482||)|
|Total other comprehensive (loss) income||(5||)||(508||)|
|Earnings per share:|
Cotiviti Holdings, Inc.
Consolidated Statements of Cash Flows
(Unaudited, in thousands)
|Three Months Ended|
|Cash flows from operating activities:|
|Adjustments to reconcile net income to net cash provided by operating activities:|
|Deferred income taxes||1,877||(5,405||)|
|Depreciation and amortization||20,774||20,042|
|Stock-based compensation expense||2,083||1,074|
|Amortization of debt issuance costs||645||1,348|
|Accretion of asset retirement obligations||48||46|
|Changes in operating assets and liabilities:|
|Accounts payable and accrued other expenses||(841||)||(2,225||)|
|Estimated liability for refunds and appeals||(774||)||2,262|
|Other long-term liabilities||247||144|
|Net cash provided by operating activities||24,572||36,353|
|Cash flows from investing activities:|
|Expenditures for property and equipment||(9,660||)||(9,467||)|
|Other investing activities||—||2|
|Net cash used in investing activities||(9,660||)||(9,465||)|
|Cash flows from financing activities:|
|Proceeds from exercise of stock options||7,363||16|
|Purchase of treasury shares||(3||)||—|
|Repayment of debt||(4,500||)||(2,025||)|
|Net cash provided by (used in) financing activities||2,860||(2,009||)|
|Effect of foreign exchanges on cash and cash equivalents||51||8|
|Net increase in cash and cash equivalents||17,823||24,887|
|Cash and cash equivalents at beginning of period||110,635||149,365|
|Cash and cash equivalents at end of the period||$||128,458||$||174,252|
|Supplemental disclosures of cash flow information:|
|Cash paid for income taxes||$||649||$||590|
|Cash paid for interest||7,587||14,565|
|Noncash investing activities (accrued property and equipment purchases)||6,738||9,052|
Reconciliation of Net Income to Adjusted EBITDA
|Three Months Ended|
(unaudited, in thousands)
|Adjustments to net income:|
|Depreciation and amortization||20,774||20,042||4||%|
|Other non-operating (income) expense(a)||(453||)||(299||)||51||%|
|Income tax expense||(861||)||5,393||NM|
|Transaction-related expenses and other(b)||731||240||205||%|
|% of revenue||36.0||%||35.5||%|
|(a)||Represents other non-operating (income) expense that consists primarily of gains and losses on transactions settled in foreign currencies. Income received for certain sub-leases is included herein.|
|(b)||Represents transaction-related expenses that consist primarily of certain expenses associated with our secondary offering in 2017 and our Initial Public Offering and other offering costs in 2016 as well as certain corporate development activity.|
|(c)||Represents expense related to equity incentive awards granted to certain employees, officers and non-employee directors as long-term incentive compensation. We recognize the related expense for these awards ratably over the vesting period.|
Reconciliation of Net Income to Adjusted Net Income
|Three Months Ended|
|(unaudited, in thousands)||2017||2016||Change|
|Adjustments to net income:|
|Amortization of Acquired Intangible Assets - Non Tax Deductible||10,402||10,402||—|
|Amortization of Acquired Intangible Assets - Tax Deductible||4,797||4,805||NM|
|Transaction-related expenses and other(a)||731||240||205||%|
|Tax effect of above adjustments(c)||(2,615||)||(2,352||)||11||%|
|Tax benefit related to stock option exercises||(10,422||)||—||NM|
|Adjusted Net Income||$||31,951||$||22,253||44||%|
|Weighted average shares of common stock - Diluted (000s)||94,905||77,757||22||%|
|Adjusted Net Income per diluted share||$||0.34||$||0.29||17||%|
|(a)||Represents transaction-related expenses that consist primarily of certain expenses associated with our secondary offering in 2017 and our Initial Public Offering and other offering costs in 2016 as well as certain corporate development activity.|
|(b)||Represents expense related to equity incentive awards granted to certain employees, officers and non-employee directors as long-term incentive compensation. We recognize the related expense for these awards ratably over the vesting period.|
|(c)||This line represents the tax impact of the amortization of acquired intangible assets - tax deductible, a portion of transaction-related expenses and other and stock-based compensation. The tax rate assumed is 38% and 40% for the three months ended March 31, 2017 and 2016, respectively.|
Adjusted EBITDA 2017 Guidance Reconciliation
(unaudited, in millions)
|2017 Guidance Range|
|Adjustments to net income (a)||177||177|
|(a)||Adjustments to net income include depreciation and amortization, interest expense, other non-operating (income) expense, income tax expense, transaction-related expenses and other and stock-based compensation. A 38% tax rate is assumed to approximate the Company's effective tax rate.|